Eccentric fixation patterns, clinical findings, and reading speed in patients with bilateral toxoplasmic macular retinochoroiditis / Padrões de fixação excêntrica, achados clínicos e velocidade de leitura em pacientes com retinocoroidite macular bilateral por toxoplasmose

ABSTRACT Purpose: To study visual acuity, refractive errors, eccentric fixation, and reading performance in patients with toxoplasmic macular retinochoroiditis. Methods: Twenty-three participants with bilateral toxoplasmic macular retinochoroiditis and 4 with toxoplasmic macular retinocho­roiditis in their unique eye were evaluated. Participants reported their eye dominance, confirmed by the Portus and Miles test. Best corrected visual acuity, spherical equivalent refraction, magnification need, and reading speed were measured. Microperimetry (MAIA, Centervue - Padova, Italy) recorded the preferred retinal locus and fixation stability by means of the bivariate contour ellipse area. Fourteen eyes from 14 normally sighted subjects served as controls. Results: Mean ± SD best corrected visual acuity was better in the dominant eye than in the nondominant eye: 0.9 ± 0.2 (logMAR 0.5 to 1.4) vs. 1.2 ± 0.3 (logMAR 0.6 to 1.7) (p<0.0001, paired t-test). Spherical equivalent myopia of -4.00 or higher was present in 42% of the eyes. Microperimetry was performed in 42 eyes. Eccentric fixation was observed in all examined eyes. In 14 eyes (33%), the preferred retinal locus was placed (in the retina) superior temporal to the macular lesion, in 10 (24%) superior nasal, in 6 (14%) inferior temporal, and in 12 (28%) inferior nasal. There was no significant difference in the distribution of the preferred retinal locus position between dominant and nondominant eyes (p=0.85, Pearson test). There was no correlation between reading speed and the distance between the preferred retinal locus and the estimated original foveal position (r=-0.09; p=0.73), the bivariate contour ellipse area (r=-0.19; p=0.44), or best corrected visual acuity (r=0.024; p=0.92). Conclusions: Myopia is more prevalent in patients with toxoplasmic macular retinochoroiditis. Reading speed is not dependent on preferred retinal locus position, stability, or visual acuity. Nevertheless, documentation of fixation provides new data on the impact of visual impairment in these patients and may be useful for rehabilitation efforts.

RESUMO Objetivo: Estudar a acuidade visual, erros de refração, fixação excêntrica e desempenho de leitura em pacientes com retinocoroidite macular por Toxoplasmose. Métodos: Vinte e três pacientes com retinocoroidite macular por Toxoplasmose bilateral e quatro com retinocoroidite macular por Toxoplasmose no seu único olho foram avaliados. Os participantes relataram sua dominância ocular, confirmada pelo teste de Portus e Miles. A acuidade visual melhor corrigida, refração em equivalente esférico, magnificação necessária e velocidade de leitura foram medidas. A microperimetria (MAIA, Centervue - Padova, Italy) registrou a estabilidade preferida do locus e da fixação da retina por meio da área da elipse de con­torno bivariada. Quatorze olhos de 14 pacientes com boa visão serviram como controles. Resultados: A média ± DP da acuidade visual melhor corrigida foi melhor no olho do­minante do que no não dominante: 0,9 ± 0,2 (logMAR 0,5 a 1,4) vs. 1,2 ± 0,3 (logMAR 0,6 a 1,7) (p<0,0001, teste t pareado). Miopia em equivalente esférico de -4,00 ou maior estava presente em 42% dos olhos. Microperimetria foi realizada em 42 olhos. Fixação excêntrica foi observada em todos os olhos examinados. Em 14 olhos (33%), o locus retiniano preferencial estava localizado, na retina, na região súpero-temporal à lesão macular, em 10 (24%) súpero-nasal, em 6 (14%) ínfero-temporal, e em 12 olhos (29%) ínfero-nasal. Não houve diferença significativa na distribuição da posição do locus retiniano preferencial entre olhos dominantes e não dominantes (p=0,85, teste de Pearson). Não houve correlação entre velocidade de leitura e distância entre o locus retiniano preferencial e a posição foveal original estimada (r=-0,09; p=0,73), a área bivariada de contorno elipsóide (r=-0,19; p=0,44) ou acuidade visual melhor corrigida (r=0,024; p=0,92). Conclusões: A miopia é mais prevalente em pacientes com retinocoroidite macular por Toxoplasmose. A velocidade de leitura não é dependente da posição do locus retiniano preferencial, da estabilidade ou da acuidade visual. A documentação do padrão de fixação excêntrica, entretanto, oferece novos dados no impacto da deficiência visual nesses pacientes e pode ser útil em estratégias de reabilitação.

Electroretinogram and visual field changes in a case of birdshot chorioretinopathy.

PURPOSE: This case report explores the role of the visual field perimetry and electroretinogram (ERG) in cases of non-infectious uveitis in the assessment and monitoring of retinal function and response to treatment. METHODS: A 59-year-old Caucasian female presenting with bilateral posterior uveitis newly diagnosed as birdshot chorioretinopathy (BSCR) presenting with bilateral decrease in visual acuity and cystoid macular edema, as well as a paracentral scotoma in the right eye. The diagnosis and follow-up of the case was done using visual field perimetry, optical coherence tomography (OCT), and ERG. RESULTS: Baseline ERG showed a marked decrease in the amplitudes of the scotopic and photopic responses and a delay of peak times mainly in the right eye. Mycophenolate mofetil at 2 g/day and oral prednisolone at 1 g/kg/day were administered with gradual tapering of the corticosteroids. After 5 months, there was a noticeable improvement in the visual acuity, macular edema in OCT, and an obvious increase in the amplitudes of the ERG associated with a decrease in peak times, particularly in the 30 Hz photopic 3.0 Flicker of the right eye. CONCLUSION: This case report highlights the importance of the peak time and wave amplitudes of the 30 Hz photopic DA 3.0 Flicker as being a sensitive parameter in the diagnosis and follow-up of BSCR.

Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review.

PURPOSE: To evaluate tocilizumab (TCZ) efficacy in severe and refractory birdshot chorioretinopathy (BSCR). METHODS: Assessment of BSCR patients refractory to conventional immunosuppressive and anti-TNF-α drugs who underwent TCZ therapy. RESULTS: Two HLA-A29 positive patients (man/37 years and woman/38 years; four affected eyes) with BSCR were studied. They had a chronic bilateral posterior uveitis. Patient 1 had been treated with intraocular and oral corticosteroids, cyclosporine A, and infliximab whereas Patient 2 received intravenous methylprednisolone pulses, cyclosporine A, azathioprine, and adalimumab. At TCZ onset they had macular edema (four eyes); visual acuity (VA) impairment (four eyes); vitritis (one eye); and diffuse angiographic signs of vasculitis (periphlebitis) (two eyes). Improvement of VA and OCT was observed following TCZ therapy in both patients. After a follow-up of 18 months (Patient 1) and 10 months (Patient 2), respectively, a corticosteroid sparing effect without any adverse effects was achieved in both cases. CONCLUSIONS: TCZ was effective in two patients with BSCR refractory to anti-TNF-α agents.

Birdshot Retinochoroidopathy: Prognostic Factors of Long-term Visual Outcome.

PURPOSE: To determine the prognostic factors of long-term visual outcome in birdshot retinochoroidopathy (BRC). METHODS: Design: Retrospective case series. Study Population: Successive HLA-A29+ BRC patients whose latest visit was between May and August 2013 at a single tertiary center (Pitié-Salpétrière Hospital, Paris). OBSERVATION PROCEDURE: Endpoint visual status (remission or deterioration) was determined for each patient based on clinical and ancillary data from the latest visit including optical coherence tomography (OCT), automated visual field (AVF), and angiograms. Main Outcome Measure: Epidemiologic, clinical, OCT, AVF, angiographic, and electrophysiological data at baseline were correlated to final visual status. RESULTS: Fifty-five patients were included. Mean observation period was 8 years (range: 0.6-23 years). Mean disease duration was 9.8 years (range: 1.2-32.7 years). Female-to-male sex ratio was 1.6:1. Factors of good visual prognosis (remission vs deterioration) included at baseline: late age of disease onset (49.5 vs 45 years, P = .05), presence of vitreous inflammatory reactions >2+ (35.9% vs 6.2%, P = .04), vascular leakage on fluorescein angiograms (FA) (44.4% vs 12.5%, P = .03), absence of macular pigment epithelium atrophy on FA (88.9% vs 62.5%, P = .05), and presence of macular edema on OCT (33.3% vs 6.2%, P = .04). Preserved electrooculography light peak and Arden ratio (P = .06) and presence of choroidal spots on infracyanine green angiograms (80.0% vs 53.3%, P = .08) seemed associated with the best prognoses. CONCLUSION: This study suggests a series of prognostic factors of long-term visual outcome in BRC. Keeping in mind the insidious evolution of the disease, knowledge of such prognostic factors should help tailor the treatment and monitoring of birdshot patients.

Visual function and macular architecture in patients with inactive zone 2 and 3 toxoplasmic retinochoroiditis / Função visual e arquitetura macular em pacientes com retinocoroidite toxoplásmica inativa nas zonas 2 e 3

ABSTRACTPurpose:To evaluate the visual function and architecture of the central and peripapillary retina in patients with inactive toxoplasmic retinochoroiditis outside the macular and peripapillary regions (zones 2 and 3).Methods:Cross-sectional study of 20 eyes (18 patients) with zone 2 and 3 toxoplasmic scars and visual acuity ≥20/25. Patients underwent Humphrey 10-2 perimetry, contrast sensitivity (Mars test), and color vision testing (L'Anthony desaturated D-15). The retinal nerve fiber layer (RNFL) and macular thicknesses were determined by optical coherence tomography.Results:The patients' mean age was 27.4 ± 10.3 years, and the mean duration of remission was 6.15 ± 5.19 months. Abnormal contrast sensitivity and color vision were observed in three (15.0%) and four eyes (20.0%), respectively. Mean deviation (MD) and pattern standard deviation (PSD) fell outside the 95% normal confidence limits of the perimeter's database in 14 (70.0%) and seven eyes (35.0%), respectively. Foveal and mean RNFL thicknesses were within the normal limits in all eyes. Eyes with zone 2 retinochoroiditis had lower foveal sensitivity than eyes with zone 3 lesions (p=0.041). Eyes with a longer duration of remission had a higher MD (r=0.575; p=0.013) and a lower PSD (r=-0.593; p=0.010).Conclusions:Despite normal central and peripapillary retinal architecture, eyes with inactive zone 2 and 3 toxoplasmic retinochoroiditis can present with abnormal color, contrast, and macular perimetric sensitivity. Zone 2 retinochoroiditis was associated with lower foveal sensitivity, and a longer duration of retinochoroiditis remission was associated with better perimetric parameters (MD and PSD).

RESUMOObjetivo:Avaliar a função visual e arquitetura da retina central e peripapilar em pacientes com retinocoroidite toxoplásmica inativa fora da região macular e peripapilar (zonas 2 e 3).Métodos:Estudo transversal de 20 olhos (18 pacientes) com cicatrizes toxoplásmicas nas zonas 2 e 3 com acuidade visual ≥20/25. Os pacientes foram submetidos à perimetria Humphrey 10-2, teste de sensibilidade ao contraste (Teste Mars) e teste de visão de cores (L'Anthony D-15 dessaturado). As espessuras da camada de fibras nervosas da retina (CFNR) e da mácula foram determinadas pela tomografia de coerência óptica.Resultados:A média de idade dos pacientes foi 27,4 ± 10,3 anos, e a duração média da remissão da retinocoroidite foi de 6,15 ± 5,19 meses. Alterações na sensibilidade ao contraste e cores foram observada em, respectivamente, 3 olhos (15,0%) e 4 olhos (20,0%). Os índices perimétricos mean deviation (MD) e pattern standard deviation (PSD) estiveram fora do intervalo de confiança de 95% do perímetro em 14 olhos (70,0%) e 7 olhos (35,0%), respectivamente. A espessura foveal e da CFNR média estiveram dentro do limite da normalidade em todos os olhos. Olhos com retinocoroidite na zona 2 tiveram menor sensibilidade foveal que olhos com lesões na zona 3 (p=0,041). Olhos com remissão de longa duração tiveram um MD mais alto (r=0,575; p=0,013) e um PSD mais baixo (r=-0,593; p=0,010).Conclusão:Apesar da arquitetura normal da retina central e peripapilar, olhos com retinocoroidite inativa nas zonas 2 e 3 podem apresentar anormalidades da visão de cores, sensibilidade ao contras e perimetria macular. A retinocoroidite na zona 2 está associada a uma menor sensibilidade foveal. Longos intervalos de remissão da retinocoroidite estiveram associados a melhores parâmetros perimétricos (MD e PSD).

Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone / Tratamento local para a retinocoroidite toxoplásmica com clindamicina e dexametasona intravítrea

ABSTRACTPurpose:To report the clinical outcomes of local treatment of toxoplasmic retinochoroiditis (TRC) with intravitreal injections of clindamycin and dexamethasone.Methods:Study population: 16 eyes (16 patients) with active TRC sparing the macula and juxtapapillary area treated with intravitreal injections of clindamycin (1 mg) and dexamethasone (1 mg) without concomitant systemic antitoxoplasmic or anti-inflammatory therapy. Measured parameters: Best-corrected visual acuity (BCVA) was measured by an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA and clinical characteristics of retinochoroiditis were assessed at baseline and at 1, 3, 6, and 12 months. Primary outcome measures: Resolution of retinochoroiditis and changes in BCVA.Results:Control of TRC was achieved in all cases with a mean interval of 2.48 ± 1.03 weeks (2-6 weeks). A single injection of intravitreal clindamycin and dexamethasone was performed in 12 patients, and four patients required two intravitreal injections, during the follow-up period. Fourteen eyes (87.5%) improved ≥ 2 ETDRS lines of BCVA, of two or more Early Treatment Diabetic Retinopathy Study lines, BCVA remained stable in two eyes (12.5%), and no patient had decreased BCVA at the end of the follow-up period. No ocular or systemic adverse events were observed.Conclusion:Local treatment with intravitreal injections of clindamycin and dexamethasone without concomitant systemic therapy was associated with resolution of TRC in patients without macular or juxtapapillary involvement. Intravitreal clindamycin and dexamethasone may represent a viable treatment option in patients with allergies or inadequate responses to oral medications.

RESUMOObjetivo:Reportar os resultados clínicos do tratamento local da retinocoroidite toxoplásmica com injeções intravítreas de clindamicina e dexametasona.Métodos:População do estudo: 16 olhos (16 pacientes) com retinocoroidite toxoplásmica ativa sem comprometimento da mácula e da área juxtapapilar, tratados com injeções intravítreas de clindamicina (1 mg) e dexametasona (1 mg) sem terapia sistêmica anti-toxoplásmica ou anti-inflamatória concomitante. Procedimento de observação: A melhor acuidade visual corrigida (BCVA) foi medida através da tabela ETDRS. A BCVA e as características clínicas da retinocoroidite foram avaliadas na qualificação, primeiro, terceiro, sexto e 12º mês. Medidas do resultado principal: resolução da retinocoroidite e mudanças na BCVA.Resultados:O controle da retinocoroidite toxoplásmica foi atingido em todos os casos com um intervalo médio de 2,48 ± 1,03 semanas (intervalo de 2 a 6 semanas). Uma única injeção intravítrea de clindamicina e dexametasona foi aplicada em 12 pacientes, e quatro pacientes precisaram de duas injeções durante o seguimento. Quatorze olhos (87,5%) melhoraram ≥ 2 linhas ETDRS de BCVA, a BCVA ficou estável em 2 olhos (12,5%) e nenhum paciente apresentou diminuição da acuidade visual no final do seguimento. Não foram observados eventos adversos sistêmicos ou oculares.Conclusão:O tratamento local com injeções intravítreas de clindamicina e dexametasona sem terapia sistêmica concomitante esteve associado com a resolução da retinocoroidite toxoplásmica em pacientes sem comprometimento macular ou juxtapapilar. A clindamicina e dexametasona intravítrea representam um tratamento promissor em pacientes com intolerância, contraindicação ou resposta inadequada a medicação oral.

Coriorretinite esclopetária / Chorioretinitis sclopetaria

O objetivo deste trabalho é relatar um caso de trauma ocular por projétil de arma de fogo, que atingiu e se alojou na cavidade orbitária, desenvolvendo coriorretinite esclopetária. Foram abordados o mecanismo fisiopatológico, os principais achados clínicos e de exames complementares, além das opções de tratamento. As características do caso relatado reforçam a importância de uma abordagem multidisciplinar no trauma ocular.

The objective of this study is to report a case of ocular trauma by gunshot bullet, which struck and lodged in the orbit, developing chorioretinitis sclopetaria. We also addressed the pathophysiological mechanism, the main clinical findings and laboratory tests, and treatment options. The characteristic of this case enhances the importance of a multidisciplinary approach in the ocular trauma.

The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis.

The authors evaluate the role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis (TRC) in four patients. Intravitreal injection of trimethoprim/sulfamethoxazole 1.28 mg/0.08 mL with dexamethasone 400 µg/0.1 mL was injected weekly or biweekly. After the initiation of treatment, a reduction in intraocular inflammation was observed clinically and on optical coherence tomography within 1 week. Three patients regained visual acuity of 20/20, and one patient improved to 20/40 with residual macular scarring. No evidence of retinal toxicity was noted on full-field electroretinogram. Intravitreal trimethoprim/sulfamethoxazole and dexamethasone combination may be an alternative treatment strategy in patients with TRC.

Long-term visual prognosis of peripheral multifocal chorioretinitis.

PURPOSE: To report on the clinical manifestations, complications, and long-term visual prognosis of patients with peripheral multifocal chorioretinitis and to search for predictors for a lower visual outcome. DESIGN: Retrospective consecutive observational case series. METHODS: setting: Institutional. PATIENT POPULATION: 134 eyes in 69 patients with a minimum follow-up period of 5 years. OBSERVATION PROCEDURE: Clinical characteristics were recorded as well as the visual acuity (VA) at the onset of uveitis; after 1, 5, and 10 years; and at the end of the follow-up period. MAIN OUTCOME MEASURES: Visual acuity, clinical features and complications, required medications and surgeries. RESULTS: The majority of the patients were elderly women with chronic bilateral ocular involvement, who developed multiple ocular complications over time. Systemic sarcoidosis was present in 39% of patients. In addition to peripheral retinal lesions and vitritis, papillitis was present in 95% of cases. The major complications included macular edema (91%), cataract (93%), glaucoma (35%), and optic disc atrophy (25%). The treatment regimens included systemic corticosteroids and/or immunosuppressive drugs in 44% of patients, and 84% of patients required intraocular surgery. One third of the affected eyes developed VA <20/40 at 5-10 years of follow-up. VA at 1 year was the most important predictor of visual outcome at 5 and 10 years (P < .001). CONCLUSIONS: Peripheral multifocal chorioretinitis was associated with a high prevalence of cataract, macular edema, optic disc atrophy, and glaucoma. Despite the chronic course of the disease, multiple complications, and surgical interventions, the majority of patients achieved satisfactory long-term visual acuity.

Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.

PURPOSE: To report the treatment outcomes of the fluocinolone acetonide intravitreal implant (0.59 mg) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy. METHODS: A retrospective case series involving 11 birdshot retinochoroidopathy patients (11 eyes). Eleven patients (11 eyes) underwent surgery for fluocinolone acetonide implant (0.59 mg). Treatment outcomes of interest were noted at baseline, before fluocinolone acetonide implant, and then at 6 months, 1 year, 2 years, 3 years, and beyond 3 years. Disease activity markers, including signs of ocular inflammation, evidence of retinal vasculitis, Swedish interactive threshold algorithm-short wavelength automated perimetry Humphrey visual field analysis, electroretinographic parameters, and optical coherence tomography were recorded. Data on occurrence of cataract and raised intraocular pressure were collected in all eyes. RESULTS: Intraocular inflammation was present in 54.5, 9.9, 11.1, and 0% of patients at baseline, 6 months, 1 year, 2 years, 3 years, and beyond 3 years after receiving the implant, respectively. Active vasculitis was noted in 36.3% patients at baseline and 0% at 3 years of follow-up. More than 20% (47.61-67.2%) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months, 1 year, 2 years, and 3 years postimplant. At baseline, 54.5% patients were on immunomodulatory agents. This percentage decreased to 45.45, 44.4, and 14.28% at 1 year, 2 years, and 3 years postimplant, respectively. Adverse events included increased intraocular pressure (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy. It is associated with significant side effects of cataract and ocular hypertension requiring treatment.

Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.

PURPOSES: To evaluate outcomes after placement of fluocinolone acetonide (FA) implants in eyes with birdshot chorioretinitis and to compare these outcomes with eyes with posterior and panuveitis. METHODS: This is a retrospective cohort study of 48 eyes from patients with posterior and panuveitis treated with FA implants from 2006 to 2010. Outcome measures include visual acuity, intraocular pressure, need for glaucoma surgery, postoperative complications, and control of inflammation. RESULTS: All eyes treated with FA implants achieved improved control of inflammation and decreased reliance on adjunctive therapy. Birdshot chorioretinitis eyes had a statistically significant increase in intraocular pressure in the first 4 months after FA implantation (P = 0.04) compared with baseline intraocular pressure. A higher percentage of eyes with birdshot chorioretinitis required glaucoma surgery and after a shorter time period after FA implantation than did eyes with other forms of posterior and panuveitis (0.42/eye-year vs. 0.11/eye-year; median time to glaucoma surgery: 15.5 months vs. 31.5 months respectively, hazard ratio, 3.4; 95% confidence interval, 1.0-10.8, P = 0.04). CONCLUSION: Although the FA implant is effective in controlling inflammation and reducing the need for systemic immunosuppressive therapy, eyes of patients with birdshot chorioretinitis tend to have a more robust intraocular pressure response to the FA implant than eyes with other types of posterior and panuveitis.

Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up.

PURPOSE: To retrospectively report a 12-month follow up for combined therapy with systemic cyclosporine A (CSA) and mycophenolate mofetil (MM) in treatment of patients with birdshot retinochoroidopathy (BSRC). PARTICIPANTS: Ninety-eight eyes of patients who received CSA and MM for the treatment of BSRC were included in the study. METHODS: All patients were followed for at least five visits during the study, or until treatment failure, or loss of follow-up. Clinical data were analysed using a Student paired t-test, Wilcoxon signed-rank test, McNemar's test, and Kaplan -Meier survival curve. Side effects related to therapy were also recorded. Main outcome measures included best-corrected logarithm of the minimum angle of resolution visual acuity, vitreous inflammation, fluorescein angiography pathologic features, and electroretinogram recordings. RESULTS: Vitreous inflammation scores at baseline and at 1 year were statistically significantly reduced in both eyes (p<0.001; p=0.001). The presence of angiographic leakage at the 1-year follow-up was significantly reduced (p=0.004). However, the presence of cystoid macular oedema (p=0.32) and comparison of electroretinogram 30-Hz amplitude revealed no significant reduction between baseline and 1-year values for either eye (p=0.61, p=0.87); nonetheless, 30-Hz implicit times were statistically significantly shorter at the end of follow-up for both eyes (p<0.001, p=0.035). Thirty-one patients (67.4%) achieved inflammation control at the 1-year endpoint. Side effects were transient, and resolved after lowering or withholding IMT for a few weeks in the majority of patients. CONCLUSIONS: These results suggest that combined IMT with CSA and MM for BSRC is well tolerated and associated with long-term control of inflammation.

OCT findings in birdshot chorioretinitis: a glimpse into retinal disease evolution.

BACKGROUND AND OBJECTIVE: Birdshot chorioretinitis is a rare disease independently involving the retina and the choroid. Retinal involvement has deleterious functional consequences. This study aimed to follow retinal profiles in early (< 1 year, untreated), intermediate (1 to 6 years, receiving therapy), and late (> 6 years) birdshot chorioretinitis. PATIENTS AND METHODS: Optical coherence tomography images were retrospectively evaluated in 28 eyes and retinal thickness was calculated in the foveola, parafoveal nasal, and temporal area; nasal and temporal mid-peripheral macula; and nasal and temporal periphery of the macula. RESULTS: Retinal thickness was significantly elevated in early birdshot chorioretinitis because of diffuse exudative retinal vasculopathy. In late disease, retinal thickness was significantly thinned at all measured locations compared with early disease. Epiretinal membrane development was observed in 92% of eyes with late birdshot chorioretinitis. CONCLUSION: The retina is thickened and exudative in early birdshot chorioretinitis, thickness diminishes during intermediate birdshot chorioretinitis, and retinal thinning/atrophy with a high rate of epiretinal membrane is observed in late birdshot chorioretinitis.

TNF-alpha gene polymorphism (-308G/A) and toxoplasmic retinochoroiditis.

AIM: To investigate the possible association between TNF-alpha (-308G/A) polymorphism and toxoplasmic retinochoroiditis (TR) in humans. METHODS: A cross-sectional study was performed which included 100 Brazilian patients with diagnosis of TR and 100 matched control subjects with positive serology to toxoplasmosis and no sign of uveitis. Genomic DNA was obtained from oral swabs of all subjects and amplified using the polymerase chain reaction (PCR) with specific primers flanking the locus -308 of TNF-alpha. PCR products were submitted to restriction endonuclease digestion and analysed by polyacrylamide gel electrophoresis to distinguish alleles, allowing the determination of the genotypes. RESULTS: There was no significant difference in the genotype (chi(2) = 0.79, p = 0.67), allele (chi(2) = 0.095, p = 0.75) and allele carriage (chi(2) = 0.70, p = 0.40) frequencies in TR patients compared with control subjects. Frequencies of the genotype (chi(2) = 2.05, p = 0.35) and allele (chi(2) = 0.13, p = 0.71) did not differ significantly between TR patients with and without recurrent episodes. CONCLUSION: This is the first study to investigate the association between TNF-alpha polymorphism and the occurrence of TR in humans. TNF-alpha gene polymorphism (-308G/A) does not seem to be associated with the occurrence or recurrence of TR.

Increased serum levels of CXCL8 chemokine in acute toxoplasmic retinochoroiditis.

PURPOSE: Chemokines have been implicated in the control of leucocyte infiltration in uveitis and in modulating angiogenesis in several ocular conditions. Toxoplasmic retinochoroiditis is a common cause of posterior uveitis. This study aimed to evaluate the serum concentrations of CC and CXC chemokines in patients with acute toxoplasmic retinochoroiditis. METHODS: The levels of five chemokines (CCL2, CCL11, CXCL9, CXCL8 and CXCL10) were evaluated in the serum of patients with active toxoplasmic retinochoroiditis (n = 55) and control subjects (n = 40). In a subset of patients (n = 18), a second measure of serum levels of chemokines was performed after the completion of oral treatment with pyrimethamine (25 mg/day), sulphadiazine (1 g, four times per day), folinic acid (7.5 mg/day) and prednisone (initial dose: 1 mg/kg/day) for approximately 30 days. RESULTS: Patients with toxoplasmic retinochoroiditis, notably those presenting with vasculitis, had increased serum levels of CXCL8 (mean +/- standard error of the mean [SEM] 35.1 +/- 6.5 pg/ml) compared with control subjects (mean +/- SEM 16.0 +/- 2.3 pg/ml; p = 0.01). There were no differences between patients and controls in serum levels of the other chemokines measured. The size of ocular lesions correlated significantly with serum levels of CXCL8 and CXCL9. After treatment, there was a significant reduction in serum levels of CXCL8. Severity of vitreous opacities did not correlate with serum levels of these chemokines. CONCLUSIONS: These data suggest a role for CXCL8 in the inflammatory process of acute toxoplasmic retinochoroiditis. Furthermore, CXCL8 may be a useful marker for patient follow-up.

Deterioration of visual function as examined by electroretinograms in Toxoplasma gondii-infected IFN-gamma-knockout mice.

PURPOSE: To investigate by ERG the effects of Toxoplasma gondii infection on the visual function of interferon gamma knockout (GKO) mice, as a model of immunocompromised hosts. METHODS: Susceptible wild-type (WT) C57BL/6 and GKO C57BL/6 mice were infected with five cysts of the avirulent T. gondii perorally. ERGs were recorded before and after the infection. The eyes of WT and GKO mice were enucleated and prepared for histologic studies 4 weeks and 12 days after infection, respectively. RESULTS: The a- and b-waves of ERGs did not change significantly up to 1 month after infection in WT mice, but those of GKO mice were significantly reduced 11 days after infection. Histopathology revealed focal retinitis and vasculitis in WT mice 4 weeks after infection. Mild inflammation and sludging of blood in the retina and choroid were found in GKO mice 12 days after infection, just before death. Cysts were found in the inner nuclear layer, with little disturbance of the surrounding retinal architecture in both WT and GKO mice. CONCLUSIONS: ERG clearly showed deterioration of visual function in GKO but not in WT mice after T. gondii infection. ERG is a sensitive and reliable method for observing activity in mice severely affected with experimental toxoplasmic retinochoroiditis.

Encephalocraniocutaneous lipomatosis associated with iris coloboma, chorioretinitis and spinal cord involvement: a case report.

A 9-year-old boy with a history of lipoma excision and laminectomy at the Th10-11 levels, resulting in incomplete paraparesis and neurogenic bladder, was admitted for a comprehensive rehabilitation programme. Physical examination revealed an ipsilateral focal dermal hypoplastic defect within an area of alopecia and a subcutaneous lipomatous tissue on the left temporo-parietal region of the scalp. Iris coloboma and chorioretinitis were diagnosed on the left eye. He also had mild mental retardation and triparesis. Magnetic resonance imaging of the brain and the spine demonstrated hyperintense masses which were consistent with lipoma. Although in the literature three cases of encephalocraniocutaneous lipomatosis (ECCL) concomitant with spinal cord involvement have been reported, to our knowledge iris coloboma and chorioretinitis in ECCL have not been reported previously. In conclusion, we would like to stress that aside from known ophthalmological malformations, iris coloboma and chorioretinitis may also be observed in ECCL and that all patients who have been diagnosed as having ECCL should be examined for spinal cord involvement.

[Birdshot retinochoroidopathy]. / La rétinochoriorétinopathie de birdshot.

Birdshot retinochoriodopathy is a bilateral posterior uveitis seen in adults over 45 years of age. The uveitis is associated with moderate vitreal inflammation, vasculides of large vessels, chronic papillitis and the yellow birdshot spots typical of the disease. The disease shows tight linkages with HLA A29 carried by more than 90% of the patients. The visual prognosis depends on the development of complications of the chronic ocular inflammation, particularly crystoid macular edema. These complications lead to lowered visual acuity which becomes a major handicap. Long-term local or general corticosteroid therapy is required and leads to cortico-dependence. An immunosuppressor (cyclosporinA) may be associated. As these treatments cause major morbidity, intravenous immunoglobulins offer a less toxic therapeutic approach. Intravenous immunoglobulins can reduce inflammatory phenomena, providing an interesting alternative for the treatment of birdshot retinochoroidopathy.